Vikram Narayan, MD, on the Future of Nadofaragene Firadenovec and Bladder Cancer

Video

Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.

Vikram Narayan, MD, built off of his research at the 21st Annual Meeting of the Society of Urologic Oncology in an interview with CancerNetwork discussing the potential future of nadofaragene firadenovec and the field of bladder cancer.

Transcription:

I think this is a very promising time for patients with bladder cancer, and in particular patients with non-muscle invasive bladder cancer who have failed BCG. When I was a resident in training, I was always struck by how few options we had to offer these patients and fortunately this is something that’s starting to change, and it’s exciting that nadofaragene may be 1 potential option for these patients in the future. There’s still a lot of work that needs to be done, but some of the discussion at SUO was trying to identify ways and sort of develop plans to study biomarkers and other tools to identify which patients will most likely not only do best with certain treatments but potentially even look at combination strategies. And then we’ll also need to study what sequence of treatments, especially as more of these agents become available. What combinations are best and in what order should they potentially be explored for these patients. Those are areas of ongoing research that will need to be delved into.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content